TG Therapeutics Files 8-K
Ticker: TGTX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1001316
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
Related Tickers: TGTX
TL;DR
TG Therapeutics filed a routine 8-K, no major news.
AI Summary
TG Therapeutics, Inc. filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates standard corporate reporting by TG Therapeutics, Inc. to the SEC, without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- TG Therapeutics, Inc. (company) — Registrant
- MANHATTAN PHARMACEUTICALS INC (company) — Former Company Name
- ATLANTIC TECHNOLOGY VENTURES INC (company) — Former Company Name
- ATLANTIC PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the reporting date for this 8-K?
The date of the report, and the date of the earliest event reported, is January 14, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina, 27560.
What is TG Therapeutics, Inc.'s IRS Employer Identification Number?
TG Therapeutics, Inc.'s IRS Employer Identification Number is 36-3898269.
Has TG Therapeutics, Inc. had previous names?
Yes, TG Therapeutics, Inc. was formerly known as MANHATTAN PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, and ATLANTIC PHARMACEUTICALS INC.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-14 16:02:03
Filing Documents
- tgtx20250114_8k.htm (8-K) — 25KB
- ex_765583.htm (EX-99.1) — 37KB
- 0001437749-25-001106.txt ( ) — 203KB
- tgtx-20250114.xsd (EX-101.SCH) — 3KB
- tgtx-20250114_def.xml (EX-101.DEF) — 11KB
- tgtx-20250114_lab.xml (EX-101.LAB) — 15KB
- tgtx-20250114_pre.xml (EX-101.PRE) — 11KB
- tgtx20250114_8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD Disclosure On January 14, 2025, the Company issued a press release entitled "TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones." For purposes of this Item 7.01, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release issued by TG Therapeutics, Inc., dated January 14, 2025. Exhibit 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TG Therapeutics, Inc. (Registrant) Date: January 14, 2025 By: /s/ Sean A. Power Sean A. Power Chief Financial Officer